Elham Hedayati

Adjunct Senior Lecturer

Karolinska Institutet
Country flag
Sweden

Research Interests

Explore related searches

Contact this professor

LinkedIn
ORCID
Google Scholar

About

Elham Hedayati is an Adjunct Senior Lecturer at Karolinska Institutet in Sweden. Her research focuses on therapeutic drug monitoring, breast cancer survival rates, and the cardiovascular toxicity associated with cancer therapies. She has contributed to various studies that examine the quality of life and the socioeconomic impacts on patients with metastatic breast cancer. Her recent work emphasizes the importance of patient-centered approaches and clinical outcomes in oncology.

Positions (1)

Publisher
source

Karolinska Institutet

Karolinska Institutet

PhD in Translational Breast Cancer Research, Molecular Oncology and Data Analysis

PhD student opportunity in translational breast cancer research at Karolinska Institutet , within Linda Lindström’s research group . The project focuses on understanding why some patients with breast cancer develop metastatic disease and die from the disease, with particular attention to molecular oncology , tumour heterogeneity , endocrine therapy , and long-term risk. The group studies breast cancer cohorts with long follow-up and uses complementary approaches that combine clinical data, statistical analysis, molecular analyses, and newer methods such as spatial proteomics and image analysis . This is a fully funded PhD studentship with a contractual salary. The position is based in an interdisciplinary and international environment at Karolinska Institutet, with collaborations across the US, the Netherlands, Norway, and Spain. The doctoral student will work on analytical and practical tasks, scientific writing, seminars, and presentations, and may also contribute to coordination of patient information and molecular work. Applicants should have a background in computational biology , biostatistics , bioinformatics , or a related field. Strong interest in cancer research, data analysis, and interdisciplinary work is important. Required eligibility includes a master’s degree or equivalent advanced study, plus English proficiency equivalent to English B/English 6. Merits include experience with breast cancer research, cancer biology, R/Python, molecular biology, and high-throughput methods such as gene expression profiling or RNA/DNA sequencing. The application deadline is 25 June 2026 . Interested candidates should review the vacancy details and submit their application through the provided portal link.

3 months ago

Articles (13)

Subtype-Specific Survival of Young Women with Breast Cancer and Its Interaction with the Germline BRCA Status

Data are scarce on the role of pathogenic germline variants in BRCA1 and BRCA2 (gBRCAm) in subtype-specific survival in young women who develop breast cancer under the age of 40. This retrospective, real-world cohort study assessed the distant disease-free survival (DDFS) and overall survival (OS) of young women diagnosed with breast cancer between 2008 and 2019 while taking into consideration the interaction of clinical subtypes and the gBRCA status. Among 473 women, HR+/Her2− was the most common subtype (49.0%), followed by TNBC (31.3%), HR+/Her2+ (13.7%), and Her2+/HR− (5.9%). The gBRCA status was known for 319 cases (gBRCAwt (wild-type – without pathogenic variants in BRCA1 or BRCA2): 204, gBRCA1m: 83, gBRCA2m: 31, 1 patient with both). The distribution of clinical subtypes varied depending on the gBRCA status (p < 0.001). In survival analysis with a median follow-up of 43 months, the unadjusted DDFS and OS were worse for gBRCAwt TNBC compared to both HR+ subtypes, but not for gBRCAm TNBC patients. T-stage, nodal involvement, and the gBRCA status were identified as significant for survival in TNBC. In TNBC, gBRCAm was associated with better DDFS and OS than gBRCAwt (5-year DDFS 81.4% vs. 54.3%, p = 0.012 and 5-year OS 96.7% vs. 62.7%, p < 0.001). In contrast, in HR+/Her2− patients, gBRCAm patients showed a tendency for worse survival, though not statistically significant. Subtype-specific survival in young women with breast cancer needs to be evaluated in interaction with the gBRCA status. For TNBC, gBRCAm is of favorable prognostic value for overall survival, while patients with gBRCAwt TNBC need to be considered to have the highest risk for adverse survival outcomes.

Year:

2024

Collaborators (18)

Luzia Travado

Head

-

PORTUGAL

Angela Denise Ives

University of Western Australia

AUSTRALIA

Lisa Rydén

Professor Surgery

Umeå Universitet Medicinska fakulteten

SWEDEN

Yuki Seidler

Universität Wien

AUSTRIA

Anna Maria Hage

Charité - Universitätsmedizin Berlin

GERMANY

Narsis Kiani

Karolinska Institutet

SWEDEN

Maria Margarete Karsten

-

GERMANY

Dan Granberg

Karolinska University Hospital

SWEDEN

Therese Djärv

Karolinska Institutet

SWEDEN

Carl Christofer Juhlin

Karolinska Institutet

SWEDEN

linetta koppert

Associate professor

Erasmus MC

NETHERLANDS

Dorothee Speiser

Charité - Universitätsmedizin Berlin

GERMANY

Regina Grossmann

Head Clinical Trials Center

University Hospital of Zurich

SWITZERLAND

Aina Johnsson

Karolinska Institutet

SWEDEN

Renske Altena-Kornalijnslijper

Karolinska University Hospital

SWEDEN

Ivan Shabo

Karolinska Institutet

SWEDEN

Irma Fredriksson

Karolinska University Hospital

SWEDEN

Frida E Lundberg

Karolinska Institutet

SWEDEN
Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI